Aura Biosciences, Inc. IPO Advisory
Share this IPO Profile:Smart Search
For IPO Boutique's "scale of 1 to 5" BUY rating on Aura Biosciences, Inc. , and our comprehensive analysis, click "Buy Market Research".
Company |
Symbol |
Price Range |
Issue Price |
Open |
Shares |
Trade Date |
| Aura Biosciences, Inc. | AURA - NASDAQ |
$14.00-$16.00 | $14.00 | $14.10 | 5.4 million | 10/29/2021 |
| Cowen, SVB Leerink, Evercore | ||||||
Co-Manager(s): BTIG | ||||||
| Health Care | ||||||
Filing(s): Filed 2021-10-08 Terms Added 2021-10-25 | ||||||
Aura Biosciences, Inc. Quote & Chart - Click for current quote - AURA
IPO Boutique aggregates information on public companies and private companies, such as "AURA" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.
About Aura Biosciences, Inc. (adapted from Aura Biosciences, Inc. prospectus):
They are a clinical-stage biotechnology company leveraging our novel targeted oncology platform to develop a potential new standard of care across multiple cancer indications, with an initial focus on ocular and urologic oncology.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
They are a clinical-stage biotechnology company leveraging our novel targeted oncology platform to develop a potential new standard of care across multiple cancer indications, with an initial focus on ocular and urologic oncology.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
IPO Boutique aggregates information on public companies and private companies, such as "AURA" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.